Global

‡ In these countries please contact our distributor

Rt Hon Alan Johnson MP opens Hull site flood defences

11 March 2016

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that Alan Johnson MP has today opened the new flood defences at its Hessle Road site in Hull.

alan johnson mp hull hessle rd

In 2013, our Hull facility was badly flooded when the River Humber burst its banks, incurring damage across the entire ground floor, including in the manufacturing factory and office areas. We worked to ensure manufacturing for customers was re-established as soon as possible, and it was through great teamwork that the facility was able to recover quickly.

Smith & Nephew has since invested more than £3 million in building flood defences around the site to prevent a reoccurrence.  The defences include the construction of two long sections of reinforced perimeter wall, with ramps and gates at the vehicle entrances. Water-tight flood doors have been fitted to all buildings on the perimeter and these buildings have also had their walls reinforced. Additionally, automatic valves have been installed in all of the connections to the sewers, in order to prevent any back-flow of contaminated water.

“We are very proud of our heritage in Hull and the site remains a major cornerstone of Smith & Nephew.” said Jonathan Procopio, Director of Global Operations. “We are bringing new programmes and products to Hull where we have a highly-skilled workforce. Protecting the future of the vital Hull site is very important to us.”

In Hull we manufacture some of the most high-technology wound care products on the market, including pioneering products such as PICO, our single use negative pressure wound therapy system. Since 2011 Smith & Nephew has invested approximately £50 million in capital projects at our Hull site. This includes moving the manufacturing of our complex silver coating technology for ACTICOAT antimicrobial dressings to Hull and installing a Film Extrusion manufacturing line. This is bespoke equipment made for the manufacture of our unique film for a range of wound products, including ALLEVYN Life advanced foam dressings.

 

Enquiries

Media

Sue Myers, Director of Communications
01482 225181
Smith & Nephew

Charles Reynolds, Corporate Communications
Smith & Nephew
020 74017646

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.


Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.